Mr. Michal Efraty reports

NEUROTHERA LABS ADVANCES ITS QUANTUM PLATFORM FOR CLINICAL DATA ANALYTICS ON A PLATFORM OF AN S&P 500 COMPANY

Neurothera Labs Inc. has completed internal validation of a proprietary quantum sampling workflow platform developed for clinical trial data analysis.

The validated workflow enables continuous probability distributions to be represented and analyzed within a quantum computing framework. The implementation was developed and evaluated using an S&P 500 company platform for hybrid quantum classical computing. The validation supports a key component of the platform's computational architecture and is expected to further expand its capabilities for addressing complex analytical challenges involving large-scale clinical and biomedical data sets.

Many real-world challenges in health care, life sciences, drug development and advanced analytics are naturally represented as continuous probability distributions. The platform's proprietary methodology converts these continuous data sets into quantum-operable energy landscape representations, enabling the application of quantum Markov chain Monte Carlo techniques while preserving the statistical characteristics of the original data.

By using the platform, quantum dynamics generate proposed samples while a classical acceptance mechanism preserves the target probability distribution. This hybrid quantum-classical architecture enables continuous data sets to be explored through quantum-generated proposals while maintaining established statistical guarantees.

The validated workflow represents an important step toward enabling increasingly sophisticated quantum-enabled analytical capabilities as quantum computing technologies continue to evolve. The company believes efficient representation of continuous data within quantum systems will play an increasingly important role in next-generation computational approaches for health care and life sciences.

The platform is being advanced through CliniQuantum, a quantum-focused technology initiative developing proprietary computational solutions for complex clinical data analytics, in which the company holds 54.01 per cent.

About Neurotera Labs Inc.

Neurothera Labs is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

We seek Safe Harbor.